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ABSTRACT 
Background: Bronchial asthma is characterized by airways inflammation and 
hyper reactivity of bronchial tissues. 
This study was performed on patients with asthma to determine their blood serum 
electrolyte values and compare them with general healthy population to assess 
whether there is a difference between them and also to assess the difference 
between intermediate and persistent asthma groups. 
 
Materials and Methods: This was a case-control study which was performed on 
patients with asthma attending Sree Mookambika Institute of Medical sciences. 
Forty-four consecutive volunteer patients with asthma according to the definite 
criteria where divided into intermittent and persistent asthma groups with twenty 
two each in each group and healthy sex and age-matched subjects were chosen. 
Secondary causes of electrolyte disturbances were ruled out. Serum blood sample 
for measuring sodium, potassium, magnesium, calcium and phosphorus value 
was obtained.   
 
Results: Significant difference between intermittent and persistent groups was 
noted (P<0.001). Hypomagnesemia and hypokalemia was detected in the 
asthmatic patients and was significant among the intermittent and persistent 
asthma groups. Findings of Hyponatremia, Hypocalcemia and 
Hypophosphatemia were insignificant. 
 
Conclusion: The study showed that asthmatic patients presented with 
Hyponatremia, Hypokalemia, Hypomagnesaemia, Hypocalcemia or 
Hypophosphatemia. The association of hypomagnesemia and hypokalemia was 
seen strongly in asthmatic patients. Between the asthmatic groups serum 
potassium, serum sodium and serum magnesium of the intermittent asthmatic 
group is found to be better compared to the persistent group. 
 
Key Words: asthma, electrolytes, intermittent, persistent, hypokalemia, 
hypomagnesemia 

BACKGROUND OF THE PROBLEM 
 
Long standing inflammatory condition of the airways is commonly known 
as asthma which affects people of all ages. It exerts a sizeable burden on the 
patients, their families, and the community.1It’s an illness due to the 
complementary action between factors that affect at molecular level and the 
external soundings. The most commonly quoted hostile factors are airborne 
pollutants which can be indoor or outdoor, high salt intake, indoor allergens, drugs 
and vaccines.2  
Respiratory symptoms are characterized with severe attacks that require 
immediate first aid, if not can lead to death. The burden of asthma is enormous, 
about 300 million people are currently suffering from asthma worldwide, and 
about 30 million are living in India.1,3 Asthma is associated with limitations in day 
to day activities, absence from school and work days, impairment of lung function, 
quality of life is reduced, and an unfavourable socioeconomic burden.150 lakh 
years are lost every year because of asthma, which is approximately 1% of the 
whole worlds burden of disease.1 
About 3-38% in children and 2-12% in adults, is currently estimated to be 
the prevalence of asthma, which is one of the commonest chronic disorder among 
children.4 An Indian Study put the prevalence of asthma in India to be around 
2.05% among those aged >15 years, with an approximate national burden of 18 
million asthmatics.5 
A large number of asthma patients are over confident about their control 
level. Exacerbations (67%) have been reported by Indian asthmatics, with a good 
amount of functional and emotional limitations.6This on the whole shows how 
poorly asthma is controlled and reflects how inadequately treatment is taken up by 
the patients. The use of bronchodilators, inhaled corticosteroids, and influenza 
vaccinations is seen in low-income countries like India.7 
Acidosis and hypoxemia can result due to the use of beta- adrenoceptor 
agonists and other sympathomimetic bronchodilators, during acute episodes of 
bronchospasm, which can increase the risk of cardiac arrhythmias.8 
It’s commonly seen and expected that a derangement exists in the serum  
potassium levels in asthmatic patients undergoing beta 2- agonist therapy.9,10 The 
first electrolyte that was found to be deranged and subsequently reported in cases 
of acute asthma was Hypokalemia and was due to beta 2-agonists and 
aminophylline therapy.11,12,13  
The long term implications of using beta 2 -agonists are tremors, 
tachycardia, palpitation, and anxiety which are commonly seen.14  Later, asthmatic 
patients treated with beta 2 agonist were also been reported with hypomagnesemia, 
hypophosphatemia, and hypocalcemia.15,16 
The adverse effects of beta 2 -agonists caused while managing acute asthma 
is one of the main reasons for the increase in mortality rate and which is still on 
the rise.17  The use of non-selective beta 2 -agonists (Isoproterenol) and Fenosterol 
for the treatment of asthma saw increased death incidence in the 1970’s.18  Cardiac 
arrhythmias can be precipitated by Hypokalemia, Hypomagnesemia and 
Hypocalcaemia.19,20  The possibility of worsening of respiratory failure during 
acute severe asthma  by the impairment of respiratory muscle performance is seen 
when there is Hypophosphatemia.21 According to Global Initiative for Asthma 
(GINA) classification of asthma,  Intermittent asthma will have <1symptom per 
week with <2 nocturnal symptoms per month. In Persistent asthma will have >1 
symptoms per week with >2 nocturnal symptoms per month.1 
There are only few studies related to above subject and its clinical 
relevance. This study is done to verify the hypothesis that the electrolyte values 
among the intermittent asthmatic patients will be found to be better than those of 
persistent asthmatic patients. 
 
 
 
 
 
 
 
 
 
  
AIMS AND OBJECTIVES 
 
1. To evaluate serum electrolyte levels in Asthmatic patients. 
2. To compare the serum electrolytes (Potassium, Magnesium, Calcium, 
Phosphate and Sodium) between Intermittent and Persistent asthmatic 
patients. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Asthma in the past 
 Towards the end of the 2nd millennium asthma was thought as a disease 
caused by factors that affect the mind and body. It was considered a hindrance to 
the advancement of medicine during that period. From the 3rd to 5th decade of the 
19th century it was considered as an illness which affects the mind and body 
together. Being termed psychological, the treatment involved psychoanalysis and 
“talking cures”. Society began to see it as an emotional outcry. Following which 
asthmatic patients were given medication to heal their depression by 
psychoanalysts. This idea was later proved wrong and it became a physical 
disease. Not until the early 1960’s Asthma was considered as an inflammatory 
disease which required anti-inflammatory medications.22 
 Hippocrates Circa 450 BC officially named asthma as a specific 
respiratory problem leading to the formation of the modern word “panting”.23 It 
was thought that Asthma was associated with emotions during the early 200BC. 24 
As a medical term it was found in the Corpus Hippocraticum written by 
Hippocrates. He suggested that the asthma spasm usually occurred in fishermen, 
garment workers and people who work with metal. 
  Aretaeus of Cappadocia (100AD) who was an ancient Greek clinician 
gave an observatory report regarding asthma. Asthma was also mentioned several 
times by Galen (130- 200 AD), who found it to be similar to Hippocrates and 
Aretaeus had mentioned about Asthma. He suggested bronchial obstructions the 
reason for asthma. Asthma originated from the lung pipes was suggested by Van 
Helmont (1579-1644 AD). A link between asthma and organic dust was noted by 
Bernardino Ramazzini (1633-1714 AD) along with exercise- induced asthma.25 
 The 1st NAEPP Expert Panel Report was published in 1991, with 
subsequent updates in 1997, 2002 and 2007 along with NHLBI which contained 
Guidelines for the Diagnosis and Management of Asthma. GINA along with 
NHLBI, NIH, and WHO published a Global Strategy for Asthma Management 
and Prevention, which gave directions towards asthma treatment. 
 
 
Classification of Asthma Severity 
 
 A decision making group along with NAEPP put forth a report known 
as the EPR2. It provided guidelines to assess symptoms of asthma and pulmonary 
function before any treatment regimen can be started. They considered parameters 
like pulmonary function and time of day and night as to when the symptoms came 
to evaluate the severity of asthma. 26  
 
 
 
 
Method of EPR 2 for Asthma Severity 
 
 
Severity Symptoms 
Night time 
Symptoms 
Lung Function 
Severe 
persistent 
Symptoms which are 
continuous, 
Physical activity limited 
Exacerbations that are 
frequent 
Frequent 
≤60% FEV1/PEF  
>30% PEF 
variability 
Moderate 
persistent 
symptoms which are 
daily, 
use of short-acting beta-
agonist daily, 
activity affecting 
exacerbations, 
≥2/week exacerbations 
In a week  >1 
>60%  FEV1/PEF 
but <80% 
>30% PEF 
variability 
Mild persistent 
>2/week Symptoms but 
<1/day, 
Activity may affect 
exacerbations 
In a month >2 
≥80% FEV1/PEF,  
20% to 30% PEF 
variability 
Mild 
intermittent 
≤2/week Symptoms,  
Between exacerbations 
Asymptomatic, 
brief exacerbations. 
In a month ≤2 
≥80% FEV1/PEF  
<20% PEF 
variability 
 
 
 
 
 The NCA in Australia27 suggested, that asthma severity be evaluated 
when a person is stable and also to consider previous course in hospital admission 
and previous exacerbations. The difficulty lies in identifying hih risk people with 
asthma as the various parameters distinguishing the hih risk and low risk is blurred.  
 
 
Method of Australian NAC for Asthma Severity 
 
Severity 
Wheeze, 
tightness, 
cough, 
dyspnea 
Night 
time 
sympto
ms 
Sympto
ms on 
waking 
Admissio
n or 
emergenc
y visits 
Previous 
life 
threatenin
g attack 
Short-
acting 
beta-
agoni
st use 
FEV
1 
PEF 
Severe 
Every 
day 
week >1 week >1 Usually 
May have 
a history 
day 
>3 to 
4 
<60
% 
<80
% 
Moderat
e 
Most 
days 
week <1 week <1 
Usually 
not 
Usually 
not 
Most 
days 
60% 
to 
80% 
80% 
to 
90% 
Mild 
Occasion
al 
Absent Absent Absent Absent 
week 
<2 
>80
% 
>90
% 
 
 
 
 
 
 
 
 
 The British Guideline on the Management of Asthma28 recommended 
that symptom controls by a person is to be evaluated individually and also to bring 
the pulmonary function back to normal with full symptom relief is not possible.
 They acknowledged the importance of control of symptoms and normal 
lung function. 
 The Canadian guidelines for asthma stated that the asthma control was 
acceptable, using parameters as to when symptoms were present day or night, 
physical activity being able to perform and the usage of first line of drugs for 
immediate relief. Asthma severity is graded depending on symptom control and 
the requirement for medication.29  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method of Canadian Consensus for Asthma Severity 
 
Severity Symptoms Treatment 
Very 
severe 
May be controlled or not 
well controlled 
use of Short-acting beta-agonist,  
corticosteroids inhalation,  
Additional inhaled therapy, 
corticosteroids taken orally 
Severe Well controlled 
Use of short-acting beta-agonist,  
corticosteroids inhalation,   
Additional inhaled therapy 
Moderate Well controlled 
Use of  Short-acting beta-agonist, 
corticosteroids inhaled Low-to-moderate 
doses, 
± Additional therapy  
Mild Well controlled 
use occasionally 
Short-acting beta-agonist,  corticosteroids 
inhaled in low doses 
Very mild Mild-infrequent rarely use Short-acting beta-agonist  
 
 
 
Classification of Asthma Severity: Method of revised GINA (2006)30:  
Intermittent 
  less than once a week symptoms 
  exacerbations are brief 
  not more than twice a month nocturnal symptoms 
  ≥80% FEV1 or PEF 
  <20% PEF or FEV1 variability 
Mild persistent 
  more than once a week but less than once a day symptoms 
  activity and sleep affecting exacerbations  
  more than twice a month nocturnal symptoms 
  ≥80% FEV1 or PEF  
  <20–30% PEF or FEV1 variability 
Moderate persistent 
  daily symptoms 
  activity and sleep affecting exacerbations 
  more than once a week nocturnal symptoms 
  short-acting β2-agonist inhaled daily 
  60–80% FEV1 or PEF 
  >30% PEF or FEV1 variability 
Severe persistent 
  daily symptoms  
  exacerbations are frequent  
  nocturnal asthma symptoms are frequent 
  physical activities Limited 
  ≤60% FEV1 or PEF 
  >30% PEF or FEV1 variability 
 
 
 
 
 
 
 
Respiratory Anatomy 
 
The components of the respiratory system are: 
 • Nose and nasal cavity 
 • Mouth 
 • Larynx  
 • Trachea  
 • Bronchial tubes  
 • Lungs 
 • Muscles of respiration  
 Two-thirds of the upper thorax is occupied by the lungs. The spine, 
heart and mediastinum bind it medially and the diaphragm binds it inferiorly. The 
inner surface of the chest wall and lung is covered by the parietal and visceral 
pleura which have a sliding contact facilitating free movement for normal 
breathing. 
 Inspiration is the respiratory activity in which there is a downward 
displacement of the diaphragm along with an upward and outward displacement 
of the ribs. This is made possible when the external intercostal muscles are made 
to contract. Expiration is a passive respiratory activity due to elastic recoil nature 
of the lungs. 
 The alveolar surface is connected to the external environment by means 
of a conducting airways which extends from the nose to the alveoli. The processes 
involved on inhalation is initially air filtration by nose, then rising the temperature 
to about 370C with addition of water vapour before being delivered to the alveoli. 
 Foreign bodies and tumours usually cause obstruction to the glottis and 
trachea as the total airway cross section is the least. Turbulent airflow in the larynx, 
trachea and main bronchi result in what we say as normal breath sounds. As we 
move away from the main bronchi towards the alveoli the air flow is very slow. It 
is mostly quiet and gas exchange takes place here by diffusion. 
 
 
Fig 1: Parts of Respiratory system 
The various branches of the respiratory path are  
  Trachea 
  main bronchus 
  lobar bronchus 
  segmental bronchus 
  conducting bronchiole 
  terminal bronchiole 
  respiratory bronchiole 
  alveolar duct 
  alveolar sac 
  alveolus 
 
  
 
 
Fig 2: Major Broncho pulmonary segments 
 
 
 
The major Broncho pulmonary segments shown in above fig 2 are:  
 Right  
 Upper lobe:  (1) Anterior,  
(2) Posterior,  
(3) Apical.  
 Middle lobe: (1) Lateral,  
(2) Medial.  
 Lower lobe: (1) Apical,  
(2) Posterior basal,  
(3) Lateral basal,  
   (4)  Anterior basal,  
(5) Medial basal. 
Left  
 Upper lobe:  (1) Anterior,  
(2) Apical,  
(3) Posterior,  
(4) Lingular.  
 Lower lobe: (1) Apical,  
(2) Posterior basal,  
(3) Lateral basal,  
   (4) Anterior basal 
 
  
 The smallest unit for gas exchange in the lung is the acinus. It consists 
of branching bronchioles and alveoli. Acinus functions as the meeting place of 
blood in pulmonary capillaries with air. Here the O2 and CO2 exchange takes 
place. Type I pneumocytes line the surface of the alveoli. Type II pneumocytes 
produce surfactant which is a phospholipid mixture preventing the surface tension 
collapsing the alveoli.31  
 There are three regions which are interconnected to help the flow of air 
from the external environment to the alveoli namely upper airway, conducting 
airway and the alveolar airway. The nose and mouth form the entry path which 
continues into the pharynx where the larynx begins from the lower part forming 
the upper airway. The air enters through the nose, it is lined with mucosal 
epithelium which sees a high content of inhaled allergens, toxicants and particulate 
matter. 
 The trachea and its branches is the starting point of the conducting 
airway. The branching causes the increase in lung surface area. The transfer to and 
from the upper airway is done by the first 16 generations of passage. These are 
made up of bronchi, bronchioles and terminal bronchioles. The main function is 
to conduct air to reach the lung. The lamina propria is attached to thin basement 
membrane above which the mucosal epithelium is attached.  
 The airways divide 23 times between the trachea and alveolar sacs. The 
transitional and respiratory bronchioles, alveolar ducts and alveoli found in the last 
7 generations form the transitional and respiratory zones. The total cross sectional 
area at the trachea is 2.5cm2 whereas at the level of the alveoli it is 11800cm2. The 
airflow velocity is very low at the alveoli. There are about 300 million alveoli in 
an average human lung with 70cm2 total area connecting with the pulmonary 
capillaries. 
 Special cells are found in the alveoli such as Pulmonary alveolar 
macrophages, lymphocytes, plasma cells, mast cells & neuroendocrine cells. 
Pulmonary alveolar macrophages (PAM) function as the defence system of the 
lung. Its origin lies in the bone marrow. It is actively phagocytic in that it ingests 
small particles missed out earlier trying to reach the alveoli. Inhaled antigens are 
also processed by the PAM by secreting molecules that are found to be attracted 
to granulocytes. At times its functioning is harmful to the human body in the 
presence of cigarette smoke or irritant leading to the formation of lysosomal 
products resulting in inflammation.32 
 The cartilaginous, membranous and gas-exchanging bronchi are the 
various components that form the respiratory bronchioles and the alveolar ducts. 
The anatomic dead space, is provided by cartilaginous bronchi and membranous 
bronchi, which also contribute to resistance of the airway. The terminal 
bronchioles, are approximately 0.5 mm in diameter.33 
 
 
 
 
 
 
 
AIRWAY CELL STRUCTURE 
 
 The various components of the airway cell structure are: 
• Mucosa,  
• Basement membrane  
• matrix of Smooth-muscle 
• fibrocartilaginous or fibroelastic-supporting connective tissue.  
 
 
 
 
 
Fig 3: Changes during respiration 
 
 
 
 
 Pathophysiology 
The major functions of respiration are   
(1) Pulmonary ventilation, exchange of air between alveoli and atmosphere, 
(2) Diffusion of oxygen and carbon dioxide from and to the alveoli and blood,  
(3) Transportation of oxygen and carbon dioxide from and to the body's tissue 
cells, 
(4) Ventilatory regulation.  
 
 The movement of the diaphragm upwards and downwards results in the 
quiet normal breathing. The contraction of the diaphragm results in inspiration and 
the relaxation of the diaphragm results in expiration causing the lungs to expel air.  
The main role of pulmonary ventilation is to constantly provide fresh new air to 
gas exchanging area of the lungs which are found close to the blood vessels of the 
lung namely the alveoli, its sacs, its ducts, and respiratory bronchioles. 
 Generally asthma is thought to be due to hypersensitive contraction to 
some foreign substances which is found in air. Allergic hypersensitivity due in to 
pollens in the majority of young patients below 30 years where as in adults and 
old age, hypersensitivity is mostly due to non-allergic substances found in air. 
 
 
 Fig 4: Airways pathology 
 
 
Mechanism in allergic asthma 
 
 Activated eosinophils and T lymphocytes are found throughout the 
airway mucosa with mucosal mast cells being activated. The disease severity is 
poorly related to the degree of inflammation. Thickening of basement membrane 
due to deposition of sub-epithelial collagen is a characteristic finding in asthma. 
This feature is seen even in those who don’t have asthma- those having 
eosinophilic bronchitis who present with cough. The lumen shows plenty of 
epithelial cells with the epithelium being very soft and having reduced connections 
with the airway wall. In fatal asthma the airway is thickened very much and is also 
edematous.  
 The mucous plug blocking the airway lumen is a common finding of 
asthma of fatal nature. The mucous plug is made of glycoproteins from the goblet 
cells along with plasma proteins which come from bronchial vessels which leak. 
Increase in the number of blood vessels is also noted along with vasodilatation. 
The airways being narrow, red and edematous can be seen by direct observation. 
INFLAMMATION 
 The bronchi shows much dominance in inflammation followed by the 
respiratory mucosa from trachea to terminal bronchioles. Allergic diseases like 
rhinitis also show a similar characteristic pattern of inflammation when compared 
with asthma. No single cell can be attributed to the main cause of asthma as there 
are many kinds of inflammatory cells involved. 
 
Mast Cells  
 The acute bronchoconstrictor response to allergens and other stimuli is 
mainly brought about by the mast cells. The other stimuli may include exercise, 
fog and even hyperventilation. They are mostly found in the smooth muscle layer 
of the airway. Normal people or patients with eosinophilic cough do not possess 
mast cells. Allergens with the help of an IgE- dependant mechanism causes the 
activation of the mast cells.  In turn it is bound with specific IgE, making it 
sensitive to activation. 
 Mast cells release histamine, cysteinyl-leukotrienes, cytokines, 
chemokines, growth factors, neurotrophins and other mediators. 
 Macrophages and Dendritic Cells  
 
 Macrophages are obtained from monocytes of the blood. They easily 
find their way into the asthmatic airways when activated by allergens. 
Inflammatory response with the release of certain cytokines is mostly due to 
macrophages. Anti- inflammatory mediators like IL-10 are also produced by such 
cells. Dendritic cells attach with allergens and process them. The allergens are 
converted to peptides which are transferred to the local lymph nodes. At the lymph 
nodes the allergenic peptides react with T- lymphocytes which initiates the 
creation T cells which are allergen specific. 
Eosinophils  
 Infiltration by eosinophils is another characteristic feature of the 
airways in an asthmatic. At the time of late reaction, there is a marked increase in 
activated eosinophils due to the inhalation of allergens. Airway 
hyperresponsiveness caused due to basic protein release and oxygen derived free 
radicals is linked to eosinophils. The eosinophils are attached to the vascular 
endothelial cells of the airway circulation which is caused by the interaction 
between the adhesion molecules. These with the help of chemokines move into the 
submucosa. Patients who are not asthmatic but are said to have chronic cough also 
show features of eosinophilic inflammation. They are also considered to be 
involved with release of growth factors which are needed for remodelling of the 
airways.   
 Neutrophils  
 Patients with severe asthma and during exacerbations show elevated 
neutrophils count in sputum and the airways. 
 
T Lymphocytes  
 The release of certain specific patterns of cytokines with a coordinated 
inflammatory response in asthma is brought about by T lymphocytes. Following 
which there is recruitment and survival of eosinophil and mast cell population in 
the airways.  
 In the normal airways TH1 cells predominate whereas the naïve immune 
system and the immune system of asthmatics are changed to express the TH2 
phenotype. TH2 cells brings about the release of IL-5 which is closely related with 
eosinophilic inflammation. 
 
Structural Cells  
 The cells of structure of the airways are cells of epithelium, airway 
smooth-muscle cells and fibroblasts. In asthma they provide inflammatory 
mediators like cytokines and lipid mediators. 
 
 
INFLAMMATORY MEDIATORS 
 In asthma many mediators have been shown to be the cause and each 
having varying effects on the airways leading to the asthmatic features. Mediators 
such as histamine, prostaglandins, and cysteinylleukotrienes contract airway 
smooth muscle, increase microvascular leakage, increase airway mucus secretion, 
and attract other inflammatory cells. 
 
Chemokines  
Inflammatory cells from the bronchial circulation are attracted into the airways by 
chemokines. 
Oxidative Stress  
 In asthma the activated inflammatory cells, such as macrophages and 
eosinophils, produce large number of ROS resulting in increased oxidative stress. 
Disease severity is related to elevated oxidative stress, which aggravate the 
response of inflammation and the response to corticosteroids. 
 
Nitric Oxide  
 Several cells along with NO synthases produce nitric oxide in the 
airways. The cells mainly involved are the epithelial cells and the macrophages. 
Patients with asthma normally expire higher levels of nitric oxide. This is closely 
associated with eosinophilic inflammation. This might be the reason for bronchial 
vasodilatation which seen in asthmatics.34 
 Abnormally large amounts of IgE antibodies are formed leading to 
allergic reactions with specific antigens. In asthmatic persons the antibodies are 
attached to mast cells which release different substance when a suitable sensitive 
substance is made contact. The released substances are  
(a) Histamine,  
(b) Anaphylaxis substance (leukotrienes mixture),  
(c) Eosinophilic chemotactic factor, and  
(d) Bradykinin.  
 
 Airway resistance is produced by the combined effects of the above 
factors including localized edema of small bronchioles, thick mucus secretion and 
spasm of smooth muscle.35 
 
 
 
The various components involved in the pathophysiology of asthma are: 
• inflammation of airway 
• obstruction of airflow  
• hyper responsiveness of  Bronchial system 
Airway inflammation 
 The various stages of inflammation in Asthma is acute, sub-acute, or 
chronic depending upon the mechanism of inflammation. Airflow obstruction and 
reactivity of bronchial tissue is because of edema of the airways and secretion of 
mucus. Different stages of eosinophil infiltration, mononuclear cell infiltration, 
mucus hyper secretion, desquamated epithelium, hyperplasia of smooth muscle 
with airway remodelling can also be seen.36 
 
Fig 5: Pathogenesis of asthma 
 
 When the airway is inflamed the most common cells that are visualised 
are macrophages, mast cells, epithelial cells eosinophils and T lymphocytes. T 
lymphocytes help in the release of numerous cytokines needed to control the 
inflammation. The long term duration of the disease is due to endothelial cells, 
fibroblasts, and epithelial cells. Selectins, integrins, and other similar adhesion 
molecules help in reducing the inflammation. Lastly, mediators of the cell cause 
the final change in airway structure which influence smooth muscle tone. 
 The overstated answer to various internal and external stimuli is seen 
as hyperresponsiveness of the airway or hyperreactivity bronchial tissues in 
asthma. The underlying cause is  smooth muscle of airways are stimulated directly 
and gets stimulated indirectly by active substances mast cells or nonmyelinated 
sensory neurons. The asthma severity is found to be correlating to the response of 
the airway. 
 
Airflow obstruction 
 A variety of changes can cause airflow obstruction, which include acute 
bronchoconstriction, edema of the airway, long standing mucous block formation, 
and airway cellular restructuring. The initial response in asthma is to constrict the 
bronchial tissues by the action of IgE dependant mediator release when in the 
presence of allergen. Later response is the edema of the airway after 6 – 24 hrs 
following an allergen challenge. The emitted fluid containing serum proteins and 
cell debris form the long standing mucous plug block which usually takes time to 
settle. Chronic inflammation leads to changes in the structure of the airway with 
remodelling of the airway, where by resolvement of the obstruction is hindered for 
reversibility.37 
  
Bronchial hyperresponsiveness 
 
 Ventilatory pump failure and hypercapnia are seen as the end result 
during exacerbations, during the inflammatory process, during the 
ventilation/perfusion (V′A/Q′) mismatching, and during increased airflow 
resistance. All of which are seen when the respiratory muscles attain fatigue.38 By 
augmenting the activation of the inspiratory muscles an increased inspiratory 
airflow resistance can be compensated39, but expiratory flow is further limited by 
the increased expiratory resistance, seen along with the reduced lung elastic recoil 
which is present in these patients.40 This is physiologically much more harmful as 
expiration is primarily an effort independent, and cannot be compensated by 
increasing the expiratory muscle effort.41 
 
 
 
 
 
 
Etiology 
 
The various factors that can cause asthma are: 
 allergens from the environment   
 Viral infections respiratory tract42 
 Exercise, hyperventilation43,44 
 GERD45  
 Long term sinusitis or rhinitis46  
 NSAID47  
 Use of beta-adrenergic receptor blockers (including ophthalmic 
preparations)  
 Obesity48  
 , tobacco smoke, pollutants of environment 
 Occupational exposure49  
 Irritants (eg, household sprays, paint fumes)  
 Various high- and low-molecular-weight compounds (eg, insects, plants, 
latex, gums, diisocyanates, anhydrides, wood dust, and fluxes; associated 
with occupational asthma)  
 Emotion, stress  
 Perinatal factors (prematurity and increased maternal age; maternal 
smoking and prenatal exposure to tobacco smoke)  
 
 
Epidemiology 
 During childhood asthma is mainly seen in boys, then during puberty it 
is seen to double in girls than boys, followed by which the distribution becomes 
equal. After puberty it is more prevalent in females, and they dominate the cases 
diagnosed in persons older than 40 years. By late adolescence boys tend to have a 
decrease in symptoms compared to girls. The reason behind such an increased 
prevalence in young adults and old age is due to limited pulmonary function and 
response of the airway.49 
 Worldwide about 300 million individuals are affected with asthma. 
Yearly, 150 lakh years are lost due to the disease burden along with reports of 
death on a large scale about 250000  is currently been estimated by the World 
Health Organization (WHO).30 
 A recent study put the prevalence of asthma in India to be around 2.05% 
among those aged >15 years, with an estimated national burden of 18 million 
asthmatics.5 A higher rate of allergic sensitization, decreased lung function, and 
significantly worse quality of life was noted in older asthmatic adults when 
compared with controls.50 
 When compared with younger patient groups, elderly patients face a 
relatively larger morbidity, mortality and expense. The reason being a high number 
of unplanned outpatient visits, emergency room visits, and asthma-related 
hospitalizations. The death rate due to asthma for patients older than 65 years is 
14 times more than patients aged 18-35 years, once the adult patient is 
hospitalized.51-54 
Treatment   
 The main aspect of treating an asthmatic patient involves the 
management of acute episodes of asthma while trying to reduce of his/ her long 
term symptoms, which include night time symptoms and symptoms arising due to 
exercise. 
Presently asthma is being more successfully treated with anti-inflammatory 
therapies. About 85% of the patients have their symptoms controlled adequately 
while using corticosteroids that are inhaled, antagonists of cysteinyl leukotriene 
receptor and/or anti-IgE Injections. 55 
 The ideal goal in treating any patient is to control symptoms, reduce the 
proportion of sickness when it starts, reduce the proportion of factors that tend to 
affect mentally and physically thereby give him/ her relief. To begin it is necessary 
to tackle the causative effects of bronchoconstriction and inflammation. To treat 
and control asthma symptoms, drugs which affect the adrenergic/ cholinergic  
bronchial smooth muscle tone as well as drugs which reduce or stop inflammatory 
processes are used. There is a balance which is maintained between the broncho 
constrictive effect of the cholinergic system and the broncho dilating effects of the 
adrenergic system on the bronchiolar smooth muscles in a normal lung. Inhaled 
short acting β2 adrenergic agonist is commonly used as a quick reliever 
medication. The controller drugs commonly used are corticosteroids that are 
inhaled, β2 agonists that are long acting, modifiers of leukotriene, cromolyn 
sodium and /or methylxanthines. The severity of the patient’s disease decides the 
route and dosage of drug administration. 
 Fig 6: Asthma management 
 
 A ladder model is presently being used to serve as a guideline which is 
divided on the basis of age into 3 groups (0-4 y, 5-11 y, 12 y and older). The 
clinical manifestations of asthma i.e symptoms, sleep disturbances, daily activity 
limitations, lung function impairment and use of rescue medications are controlled 
in many patients with appropriate treatment. When asthma is controlled, there 
should be no more than occasional recurrence of symptoms and severe 
exacerbations should be rare.56 
 
Biochemical aspect of asthma 
  It is distinguished by an unstable airflow obstruction which is 
secondary compared to the pattern seen in allergic airway inflammation. In which 
inflammatory cells like eosinophils and T-helper 2 (TH2)57 cells are seen 
infiltrating and allergens are seen activating resident mast cells and dendritic 
cells.57,58 Activated inflammatory cells and inflammatory mediators are produced 
by the structural cells, such as airway epithelial cells and smooth muscle cells. 
Increased number of airway smooth muscle cells, fibrosis, angiogenesis, and 
hyperplasia of mucus-secreting cells are some of the structural changes in the 
airways due to chronic inflammation. Many cytokines and chemokines along with 
multiple inflammatory mediators bring about this complex chronic 
inflammation.59 
 The interaction of cells involved in the human airway tissues such as 
the lymphocytes, mast cells, basophils, airway epithelial cells and airway smooth 
muscle were confirmed using murine models and majority found to be true in 
humans too. 58,60,61 
 Routine inspection of the airway is not possible, so airflow obstruction 
is used as an alternative means for assessing asthmatic airway inflammation. FEV1 
is an important component in asthmatic airflow obstruction.62 Airway 
inflammation cannot be measured by FEV1 or by any other measures of airflow 
obstruction.63 Hence anti-inflammatory drugs along with corticosteroids have been 
used because of their anti-inflammatory effect. The problem begins when these 
medications are slowly weaned. A balance between weaning without which can 
result in serious harmful side effects on the long run along and the increase in 
exacerbations has to be maintained.58,62,63 
Beta agonist - They are the most effective bronchodilators while treating asthma, 
as they act as functional antagonists and as well as relax the smooth muscle cells 
of the airway.64 
 
Mechanism of bronchodilation 
 
The mechanism of broncho dilation can be divided into: 
• Classical signalling.  
• Alternative signalling.  
 
Fig 7: Mechanism of brochodilation 
 
 
Classical signalling  
 In the classical signalling the β2 agonist initially binds with the β2 
agonist receptor (β2AR). This is then coupled to a stimulatory protein GS. This 
protein GS combines with Adenyly cyclase (AC) forming cyclic adenosine 
monophosphate (cAMP) using ATP. The cAMP becomes an exchange protein 
adenylyl cyclase (EPAC) known to inhibit cell proliferation.64,65  Meanwhile 
cAMP can also activate Proteinkinase A along with Calcium ions forming Myosin 
light chain kinase (MLCK) in the smooth muscle cells of the airway resulting in 
its relaxation. The MLCK gets inhibited when β2AR couples with GS to a calcium 
activated potassium channel (BKCa) through which, intercellular calcium is 
reduced and Myosin light chain phosphokinase is activated. 
 
 
Alternative signalling  
 In this signalling, the phospholipase C (PLC) is activated by the β2AR 
and βγ-subunits of Gα and Gq and via Gαq. β-arrestin-2 is also found to also 
interact with β2AR, which interacts with p38 (Mitogen activated 
proteinkinase)MAPK and Phosphoinositide 3-kinase (PI3K). These pathways 
increase proteins of inflammation which have a harmful effect over the 
asthma.The airway smooth muscle cell proliferation gets inhibited by β2-agonists 
which is due to EPAC rather than PKA.64,66 
 Airway the smooth muscle of the airways are usually resistant to β2AR 
desensitization, because of a large receptor reserve and a very low level of 
expression of the enzyme G-protein receptor kinase-2 (GRK2). The β2-receptors 
are inactivated and phosphorylated by GRK2.67 
 An alternative way in which  β2 agonist work is by restricting 
inflammatory cells from producing bronchoconstrictor mediators and airway 
nerves from producing neurotransmitters. For example, β2-agonists inhibit the 
release of mediators from mast cell by GS coupled to Ca2+-activated K+ channel.68 
 
 
 
Conditions that mimic bronchial asthma 
There are times when the respiratory can produce sounds similar to that of asthma 
which may be confusing to the clinician. The commonly seen conditions are:  
• Vocal cord dysfunction  
 At times Vocal cord dysfunction may be seen as a single entity or 
combined with asthma.  The reason being - paradoxical adduction of the vocal 
cords while breathing in, which becomes absent with panting, speech, or 
laughing.69   
• Tracheal and bronchial lesions  
 There are various reports suggesting that airway tumors such as 
endobronchial carcinoid and mucoepidermoid tumours can also create symptoms 
just like asthma.70 
• Foreign bodies  
 Wheezing as such is known to occur in infants and adults. When a 
foreign body is aspirated, it causes generalised wheezing or localized wheezing 
leading to symptoms like asthma.71 
• Pulmonary migraine  
 Recurrent asthma, thick mucoid sputum with cough, lower back pain to 
the shoulder with nausea and vomiting is pulmonary migraine which is associated 
with focal headaches.72 
 
• Congestive heart failure  
 The feeling of dyspnea and wheezing due to enlarged lung vessels and 
interstitial pulmonary edema causes congestive heart failure. The presence of 
wheeze secondary to bronchospasm is seen in cardiac asthma which can give rise 
to paroxysmal nocturnal dyspnea and coughing.73 
• Diffuse panbronchiolitis  
 A condition called diffuse panbrocholitis is known to have symptoms 
like bronchial asthma along with wheeze, cough, and sinusitis with dyspnoea on 
exertion.74 
• Aortic arch anomalies75  
• Sinus disease76 
• Gastroesophageal reflux77    
 
Electrolytes 
 
 Electrolytes are divide into anions that are ions with negative charge 
which move toward the positive electrode, or cations that are ions with positive 
charge that move toward a negative electrode. The major electrolytes are Na+, K+, 
Cl− and HCO3− which are found primarily as free ions, compared to Ca2+, Mg2+, 
and other trace elements which are mainly protein bound.78 
In a healthy person, 60 % of the body weight is body water.  Body water is of two 
types namely ECF and the ICF, with a cell membrane in between.  With the help 
of   Na, K ATPase pump, equilibrium between the two compartments is 
maintained, where by Na being the main extracellular cation and K the main intra-
cellular cation. The capillary membrane divides the ECF into intravascular and 
interstitial compartments. The membrane pore size, the relative concentration and 
oncotic pressure of proteins decides the equilibrium between the 
compartments.79,80 
Sodium  
 The major cation of extracellular fluid is Sodium. It maintains the 
normal water distribution along with osmotic pressure of the ECF. The body 
requires 1 to 2 mmol/d, over which gets excreted by the kidneys. 
Potassium 
 The major intracellular cation is Potassium. In tissues, the average 
concentration is 150 mmol/L, where as in the erythrocytes the concentration is 105 
mmol/L. An average dietary intake of 2.4 to 4.4 g/d is needed daily to maintain 
the requirement. Potassium is rapidly distributed after being absorbed from the GI 
tract, cells take up a small amount, and mostly excreted by the kidneys. After 
glomeruli filtration it is completely reabsorbed by the proximal tubules and finally 
secreted in the distal tubules in exchange for Na+ under the influence of 
aldosterone. 
Magnesium  
 The fourth major cation in the body is Magnesium as well as the second 
most major intracellular cation. The cellular concentration of magnesium has a 
range of 2.4 to 7.3 mg/dl. Usually if the cell has more metabolic activity then there 
would be more magnesium as it is bound to the clleular ATP. Increased nerve 
conduction velocity with lowered threshold of axonal stimulation is seen when 
there is low serum magnesium. Neuro muscular excitability is increased due to 
reduced serum magnesium resulting in various metabolic abnormalities. 
 
Calcium 
. Calcium is the most prevalent cation in the body about 1000mg in the 
free calcium form and is the active biological form. It plays an important role in 
muscle contraction, hormone secretion, glycogen metabolism, and cell division as 
intercellular calcium. Maintains intercellular calcium, bone mineralization, blood 
coagulation and plasma membrane potential as extracellular calcium. Decreased 
calcium is known to cause increased neuromuscular excitability and tetany. 
 
Phosphorus 
 An adult body is said to contain has 600 g of phosphorus in the form of 
inorganic and organic phosphates. About 10% of the phosphate in serum is 
protein-bound; 35% is complexed with sodium, calcium, and magnesium; and 
55% is free. Being an important component of hydroxyapatite, it plays an 
important role in body structure.  
 
Conditions causing electrolyte imbalance: 
 The human body during the time of sickness and disease is known have 
some sort of electrolyte disturbance. The most common electrolyte disturbances 
are conditions which arise due to high and low sodium, potassium, calcium and 
magnesium.78 
 A plasma Na+ concentration <135 mmol/L is said to be Hyponatremia 
which is  seen in conditions such as Hyperlipidemia, Hyperproteinemia, 
Posttransurethral resection of prostate/bladder tumor, Hyperglycemia, 
Integumentary loss as in sweating & burns, Gastrointestinal lossas seen in with 
vomiting, tube drainage, fistula, obstruction, Diarrhea, Renal loss as with diuretics, 
osmotic diuresis, hypoaldosteronism, salt-wasting nephropathy, post obstructive 
diuresis, nonoliguric acute tubular Necrosis, Primary polydipsia, Chronic renal 
insufficiency, Heart failure, Hepatic cirrhosis and Nephrotic syndrome.81 
 A plasma Na+ concentration >145 mmol/L is Hypernatremia which is 
seen in primary hypodipsia, loss of water from GI tract, insensible loss of water 
due to evaporation from skin and respiratory tract, renal water loss due to drugs or 
diabetes insipidus. 
 A plasma K+ concentration <3.5 mmol/L, is Hypokalemia which is 
seen in conditions such as Starvation, Clay ingestion, Metabolic alkalosis, insulin 
secretion disorder,β2 adrenergic receptor agonists, α blockers, TPN, 
Pseudohypokalemia, Hypothermia, Hypokalemic periodic paralysis, Barium 
toxicity, Gastrointestinal loss (diarrhea), Integumentary loss (sweat), Increased 
distal flow: diuretics, osmotic diuresis, salt-wasting nephropathies, Increased 
secretion of potassium as in primary hyperaldosteronism, secondary 
hyperaldosteronism (malignant hypertension, renin-secreting tumors, renal artery 
stenosis, hypovolemia), apparent mineralocorticoid excess (licorice, chewing 
tobacco, carbenoxolone), Congenital adrenal hyperplasia, Cushing’s syndrome, 
Bartter’s syndrome, distal delivery of non-reabsorbed anions: vomiting, 
nasogastric suction, proximal (type 2) renal tubular acidosis, diabetic ketoacidosis, 
glue-sniffing (toluene abuse) & penicillin derivatives. 
 A  plasma K+ concentration >5.0 mmol/L is Hyperkalemia which is 
seen in Renal failure, decreased circulating arterial volume, decreased as 
potassium secretion conditions such as Primary and secondary hypoaldosteronism, 
and enhanced Cl- reabsorption. 
 Hypercalcemia is usually seen in excessive PTH production, 
malignancy, Excessive 1,25(OH)2 D production, Primary increase in bone 
resorption, Excessive calcium intake and Endocrine disorders such as adrenal 
insufficiency and pheochromocytoma.  Hypocalcaemia is usually seen with 
Parathyroid agenesis, Parathyroid destruction, Reduced parathyroid function, 
Vitamin D deficiency, Parathyroid hormone resistance syndromes, Acute 
pancreatitis and Acute rhabdomyolysis.82  
 A plasma concentration below 1.7 mg/dl is called as hypomagnesemia 
which can be due to malabsorption from the intestine, vomiting, diarrhea or 
drainage from the intestine. The rapid movement of magnesium into cells, bone or 
third spaces from the ECF is also another cause. Hypermagnesemia is usually seen 
when there is a defect in the renal excretion as normally large quantities of 
magnesium can be excreted out without any problem.83 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
SOURCES OF DATA 
 Patients and bystanders who attended the medicine OPD of Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Tamilnadu for routine 
medical check-up formed the subjects for the present case control study. A total of 
88 subjects that came to the hospital were divided into 44 control and 44 cases (22 
intermittent and 22 persistent asthmatic cases) during January 2015 to July 2015 
was enrolled into the study. 
 
INCLUSION CRITERIA 
1. All patients diagnosed with asthma without any comorbidities attending 
medicine outpatient department and casualty of Sree Mookambika Institute of 
Medical Sciences grouped into intermittent and persistent depending on their 
severity of asthma. 
2. Age between 18 to 60 years                                  
3. Normal persons without asthma and any other comorbidities.                                                                                                                                               
 
EXCLUSION CRITERIA 
1. Patients excluded were -Cardiovascular disease/ Diabetic/ alcoholic/ chronic 
kidney diseases/ diarrhoea/ pregnancy/ on diuretics/ drugs producing 
bronchospasm 
2. Those who are not willing to participate. 
 
METHOD OF COLLECTION OF DATA 
 
 Informed consent taken from the subjects after explaining the 
procedure. The data was collected using an organised pro forma. Baseline data 
including age, gender, occupation, detailed medical history including number of 
symptoms per week and number of nocturnal symptoms per month, clinical 
examinations and relevant investigations were included as part of the 
methodology.  
 
 The following parameters were collected: age, gender, religion, blood 
pressure and clinical chemistry parameters. Blood samples (2ml) were collected 
in clot activator Vacutainer from each participant while employing standard 
infection prevention procedures. The serum was obtained after centrifuging the 
blood for 5 min at 2500 rpm. The serum samples were then used to determine the 
concentrations of Sodium, Potassium, Magnesium, Calcium and Phosphorus.  
1. ESTIMATION OF SODIUM & POTASSIUM (Ion selecting electrode 
method)84 
Clinical significance 
 Most metabolic processes are affected by electrolytes.  They help to 
maintain osmotic pressure and various body fluid compartments hydration, pH of 
the body, and heart and muscle functions regulation.  Electrolytes are also involved 
in oxidation-reduction reactions and participate as essential parts or cofactors in 
enzyme reactions. 
 
Principle 
The Beckman Coulter AU System ISE module for Na+, K+, and Cl- uses crown 
ether membrane electrodes for sodium and potassium. For a specific ion an 
electrical potential is developed according to Nernst equation. This electrical 
potential is compared with internal reference solution and converted in voltage 
followed with sample ion concentration.   
Reagents required: 
 
ISE Buffer  ISE Reference  
Triethanolamine 0.1 mol/L Potassium Chloride 1.0 mol/L 
Preservatives  Preservatives  
  
ISE Mid Standard                                                Internal Reference Solution  
    
Sodium  4.3 mmol/L Potassium Chloride 3.3 mol/L 
Potassium  0.13 mmol/L Silver Chloride Saturated 
Chloride 3.1 mmol/L Preservatives  
Preservatives    
 
 
ISE Low Serum Standard        ISE High Serum Standard        
Sodium  130 mmol/L Sodium  160 mmol/L 
Potassium  3.5 mmol/L Potassium 6.0 mmol/L 
Chloride 85 mmol/L Chloride 120 mmol/L 
Preservatives  Preservatives  
 
 
Na+ Selectivity Check 
Solution  
 K+ Selectivity Check 
Solution  
 
Sodium 150 mmol/L Potassium 5.0 mmol/L 
Preservatives  Preservatives  
 
Sample: 
 Serum heparinised plasma or EDTA plasma used. 
 Specimens should be separated from cells as soon as possible after 
collection 
 Do not use samples with hemolysis may falsely elevate potassium values. 
 If plasma must be used, the recommended anticoagulants are lithium 
heparin and ammonium heparin.   
 
Handling Conditions: 
 Use fresh sample to test. 
 At 2-8ºC sodium and potassium is stable for 7 days. 
 Do not freeze the reagents. 
 The samples are stored in a stoppered tube if analysis is delayed.  
 
REFERENCE RANGES: 
Serum:       
Na+: 136 – 145 mmol/L     
K+:    3.5 – 5.1 mmol/L                  
Cl-:   98 – 107 mmol/L     
 
Preparation: 
The reagents are liquid which is readily useable. No extra preparation is 
needed.  ISE electrodes are readymade and can be attached to the on board 
analyzer. 
 
Storage Requirements 
 When stored at 2 – 250C, unopened reagents and standards are stable until 
the date of expiry printed on the label.  
 When opened and stored in the ISE reagent compartment of the analyzer. 
ISE Buffer, ISE Mid-Standard, and ISE Reference Solution are stable for 
90 days.   
 After opening, ISE Low and High Serum Standards, ISE Urine Low/High 
Standard, and Na/K Selectivity Check Solutions may be stored at 2 - 25C 
for up to 90 days provided the cap is replaced immediately after use.   
 ISE Internal Reference Solution may be stored at 15- 25C for up to 90 days 
provided the cap is replaced immediately after use. 
 
Precautions: 
 1. The ISE Reagents and Standards are for in vitro diagnostic use. 
 2. Not to be ingest. It is harmful if swallowed. 
 
2. Estimation of Magnesium (Xylidyl blue method)85,86  
PRINCIPLE 
In an alkaline medium a coloured complex is formed by magnesium when 
it reacts with Xylidyl blue. With the help of spectrophotometry this colored 
complex is measured. The calcium interference is removed by the addition of 
EGTA. 
REAGENTS 
A. Reagent.  
 Sodium Carbonate 0.1 mol/L  
 EGTA 0.1 mmol/L,  
 Triethanolamine 0.1mol/L,  
 Potassium Cyanide 7.7 mmol/L,  
 Sodium Azide 0.95 g/L. 
B. Reagent.  
 Glycine 25 mmol/L,  
 Xylidyl blue 0.5 mmol/L,  
 Chloroacetamide 2.6 g/L. 
S. Calcium/Magnesium Standard.  
 Calcium 10 mg/dl,  
 Magnesium 2 mg/dl (0.82mmol/L).  
 Aqueous primary standard. 
 
SAMPLES 
 Serum collected by following standard techniques of blood collection.  
 Hemolysed and lipemic samples are not suitable. 
 Serum Magnesium is stable for 10 days at 2-8ºC. Use heparin as 
anticoagulant. 
 
Reagent reconstitution 
Reagents and standard are provided ready to use. 
 
Procedure 
The assay was carried out using Au 480 beckmann coulter autoanalyser. 
 
REFERENCE VALUES 
Serum and plasma: 1.7-2.4 mg/dl = 0.70-0.98 mmol/L. 
 
STORAGE 
Store at 2-8ºC. 
Until the expiry date Reagents and Standard are stable when stored tightly closed 
and if contaminations are prevented during their use. 
 
3. ESTIMATION OF CALCIUM (by ARSENAZO III method)87 
PRINCIPLE 
                                             Neutral pH 
Calcium + Arsenazo III                                         Blue colored complex 
A colored complex is formed when arsenazo III reacts with the calcium present in 
the sample which is spectrophotometrically measured. 
 
 
REAGENTS 
Reagent.  
Arsenazo III 0.2 mmol/L,  
imidazole 75 mmol/L. 
 
SAMPLE 
• Serum collected by following standard techniques of blood collection.  
• Hemolysed and lipemic samples are not used. 
• Calcium in serum or plasma is stable for 10 days at 2-8ºC. Anticoagulants 
other than heparin should not be used. 
 
Procedure 
The assay was carried out using Au 480 beckmann coulter autoanalyser. 
 
REFERENCE VALUES 
Serum and plasma: 8.6-10.3 mg/dl = 2.15-2.58 mmol/L 
 
REAGENT PREPARATION 
Reagent and Standard are ready to use. 
STORAGE 
Store at 2-8ºC. 
Reagent and Standard are stable until the expiry date shown on the label when 
stored tightly closed and if contaminations are prevented during their use. 
 
4. ESTIMATION OF PHOSPHORUS (by Phosphomolybdate/UV method)88 
PRINCIPLE 
           ACID pH 
Phosphorus + Ammonium molybdate                        Phosphomolybdate complex 
 
In an acid medium, molybdate reacts with inorganic phosphorus to form a 
phosphomolybdate complex which at 340nm is measured spectrophotometrically. 
Reagent  
Reagent:  
 Sulfuric acid 0.36 mol/L,  
 Sodium chloride 154 mmol/L, 
 Ammonium molybdate 3.5 mmol/L 
 Preservatives  
SAMPLE 
Serum collected by following standard techniques of blood collection. Phosphorus 
in serum or plasma is stable for 7 days at 2-8ºC.  
 
PROCEDURE 
The assay was carried out using Au 480 beckmann coulter autoanalyser. 
 
REFERENCE VALUES 
Serum: Adults: 2.5-4.5 mg/dl  
 
REAGENT PREPARATION 
Reagent and Standard are ready to use. 
 
STORAGE 
Store at 15-30ºC. 
 Reagents and Standard are stable until the expiry date shown on the 
label when stored tightly closed and if contaminations are prevented during their 
use. 
 
STATISTICAL ANALYSIS 
 Data collected were entered in excel. Percentage, Mean and Standard 
deviation were calculated. Appropriate test of significance like independent 
students “t” test and Fisher’s exact test were done. Values were considered 
statistically significant if p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
RESULTS 
 RESULTS 
The present study was undertaken to evaluate the significance of possible 
electrolyte abnormality in asthmatic patients. 44 Asthmatic patients divided into 2 
groups of 22 each intermittent and persistent were considered with 44 healthy 
individuals chosen as controls. 
 
GENERAL CHARACTERISTICS OF THE STUDY POPULATION 
 5.1  AGE 
Table 5.1  
Age Control Case 
Number Percentage Number Percentage 
18 to 20 years 1 2 4 9 
21 to 30 years 6 14 6 14 
31 to 40 years 8 18 4 9 
41 to 50 years 10 23 13 30 
51 to 60 years 19 43 17 38 
Total 44 100 44 100 
 
 
 
  
Table 5.2 
 
Age Number Mean Std. Deviation 
Control 44 44.56 12.53 
Intermittent 22 43.59 14.83 
Persistent 22 43.59 12.9 
 
Table 5.1, gives the distribution of the study samples according to the age 
and graphically represented in fig 8. The cases and controls are divided into 5 
groups (18 -20years, 21-30yrs, 31-40yrs, 41-50yrs, and 51-60yrs). It shows the 
maximum numbers of controls are in the age group of 51-60yrs (43%) and the 
majority number of cases is also of 51-60yrs (38%). Table 5.2 gives the mean age 
of the control group as 44.56 years and that of the intermittent and persistent cases 
as 43.59 yrs. The age of the youngest person who participated in this study is 18 
years and the oldest is 60 years with the mean age of 44.1 years. 
 
 
 
 
 
 
  
Fig 8: Age distribution 
 
 
5.2  GENDER 
Table 5.2 Sex Distribution 
Sex 
Control Case 
Number Percentage Number Percentage 
Male 27 61 20 45 
Female 17 39 24 55 
Total 44 100 44 100 
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Out of 44 persons who participated in this study as control, 27 were males (61%), 
followed by 17 females (45.3%) whereas females were more in the case group 
with 24 females (55%) followed by males at 20 with 45%. 
 
Fig 9: Sex distribution 
 
 
 
Male 
61%
Female
39%
Control
  
 
5.3 Distribution of Electrolyte parameters 
 
Table 5.3 
 
 
Hyponat
remia 
Hypokalem
ia 
Hypomagn
esemia 
Hypocalca
emia 
Hypophosp
hatemia 
n % n % n % n % n % 
Control (44) 13 29 0 0 1 0 21 95 0 0 
Intermittent 
(22) 
18 81 12 54 22 100 22 100 22 100 
Persistent 
(22) 
21 95 21 95 22 100 20 90 21 95 
 
Male 
45%
Female
55%
Case
Table 5.3 shows the general distribution of the abnormal electrolytes between the 
cases and the control group. 95% of the persistent group is said to have 
Hyponatremia followed by the intermittent and control group. Persistent group 
shows high distribution 95% for Hypokalemia, followed by intermittent with 0% 
for control. 100% is seen in both intermittent and persistent group. About 90% of 
the study population is seen to have hypocalcaemia. 100% hypophosphatemia is 
seen in the intermittent group followed by 95% in persistent group and nil in 
control. 
 
 
5.4 Comparison of serum Sodium between controls and cases 
 
Comparison of serum Sodium between controls and cases is shown in table 5.4-1, 
2, 3 and graphically represented in fig 10. The difference in mean Serum sodium 
levels between (intermittent and persistent) cases and controls is statistically 
significant (P<0.05). More over the difference in mean Serum sodium levels 
between intermittent and persistent cases is also statistically significant. 
Table 5.4-1 
 N Mean Standard Deviation 
(±) 
P value 
Control 44 136.54 2.56  
Case -I 22 134.63 0.9 0.001 
 
Table 5.4-2 
 N Mean Standard Deviation 
(±) 
P value 
Control  44 136.54 2.56  
Case - P 22 132.72 1.93 <0.0001 
 
 
 
Table 5.4-3 
 N Mean Standard Deviation 
(±) 
P value 
Case - I 22 134.63 0.9  
Case - P 22 132.72 1.93 <0.0001 
 
 
Fig 10: Comparison of mean serum Sodium 
  
 
 
5.5 Comparison of serum Potassium between controls and cases 
Comparison of serum Potassium between controls and cases is shown in table 5.5-
1, 2, 3 and graphically represented in fig 11. The difference in mean Serum 
Potassium levels between (intermittent and persistent) cases and controls is 
statistically significant (P<0.05). More over the difference in mean Serum 
Potassium levels between intermittent and persistent cases is also statistically 
significant. 
 
136.54
134.63
132.72
126
128
130
132
134
136
138
140
Control Case - I Case - P
m
Eq
/L
Group
Serum Sodium
Table 5.5-1 
 N Mean Standard Deviation 
(±) 
P value 
Control 44 4.37 0.53  
Case - I 22 3.89 0.89 0.008 
 
Table 5.5-2 
 N Mean Standard Deviation (±) P value 
Control 44 4.37 0.53  
Case – P 22 3.22 0.19 <0.0001 
 
 
Table 5.5-3 
 N Mean Standard Deviation 
(±) 
P value 
Case - I 22 3.89 0.89  
Case - P 22 3.22 0.19 0.001 
 
Fig 11: Comparison of mean serum Potassium 
 
 
 
 
5.6 Comparison of serum Magnesium between controls and cases  
Comparison of serum Magnesium between controls and cases is shown in table 
5.6-1, 2, 3 and graphically represented in fig 12. The difference in mean Serum 
Magnesium levels between (intermittent and persistent) cases and controls is 
statistically significant (P<0.05). But the difference in mean Serum Magnesium 
levels among intermittent and persistent cases is not statistically significant. 
 
4.37
3.89
3.22
0
2
4
6
Control Case - I Case - P
m
Eq
/L
Group
serum Potassium
Table 5.6-1 
 N Mean Standard Deviation 
(±) 
P value 
Control 44 1.96 0.22  
Case - I 22 1.44 0.15 <0.0001 
 
Table 5.6-2 
 N Mean Standard Deviation (±) P value 
Control 44 1.96 0.22  
Case - P 22 1.32 0.62 <0.0001 
 
Table 5.6-3 
 N Mean Standard Deviation 
(±) 
P value 
Case - I 22 1.44 0.15  
Case - P 22 1.32 0.62 0.392 
 
 
 
 Fig 12: Comparison of mean Serum Magnesium 
 
 
 
5.7 Comparison of serum Calcium between controls and cases  
Comparison of serum Calcium between controls and cases is shown in table 5.7-
1, 2, 3 and graphically represented in fig 13. The difference in mean Serum 
Calcium levels between (intermittent and persistent) cases and controls is 
statistically significant (P>0.05). The difference in mean Serum Calcium levels 
between intermittent and persistent cases is not statistically significant. 
 
Table 5.7-1 
1.96
1.44
1.32
0
0.5
1
1.5
2
2.5
Control Case - I Case - P
m
g/
d
l
Goup
Serum Magnesium
 N Mean Standard Deviation (±) P value 
Control  44 8.55 0.69  
Case -I 22 7.7 0.67 <0.0001 
 
Table 5.7-2 
 N Mean Standard Deviation 
(±) 
P value 
Control 44 8.55 0.69  
Case - P 22 8.01 0.74 0.005 
 
Table 5.7-3 
 N Mean Standard Deviation (±) P value 
Case - I 22 7.7 0.67  
Case - P 22 8.01 0.74 0.152 
 
 
Fig 13: Comparison of mean serum Calcium 
  
 
 
5.8 Comparison of serum Phosphorus between controls and cases 
Comparison of serum Phosphorus between controls and cases is shown in table 
5.8-1, 2, 3 and graphically represented in fig 14. The difference in mean Serum 
Phosphorus levels between (intermittent) cases and controls is statistically 
significant (P<0.05). The difference in mean Serum sodium levels between 
intermittent and persistent cases is not statistically significant. 
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Table 5.8-1 
 N Mean Standard Deviation 
(±) 
P value 
Control  44 4.24 0.57  
Case - I 22 2.29 0.1 <0.001 
 
Table 5.8-2 
 N Mean Standard Deviation 
(±) 
P value 
Control  44 4.24 0.57  
Case - P 22 2.29 0.27 <0.001 
 
Table 5.8-3 
 N Mean Standard Deviation 
(±) 
P value 
Case - I 22 2.29 0.1  
Case - P 22 2.29 0.27 1 
 
 
 
 Fig 14: Comparison of mean serum Phosphorus 
 
 
5.9 Distribution of electrolytes between cases 
Table 5.9 
 
Hyponatre
mia 
Hypokale
mia 
Hypomag
nesemia 
Hypocalc
aemia 
Hypophos
phatemia 
 Yes  No Yes No Yes No Yes No  Yes No 
Intermittent 18 4 14 8 22 0 22 0 22 0 
Persistent 21 1 21 1 22 0 20 2 21 1 
p-value 0.345 0.021 N/A 0.488 1 
4.24
2.29
2.29
0
2
4
6
Control Case - I Case - P
m
g/
d
L
Group
Serum Phosphorus
significance NS S S NS NS 
  
 
Table 5.9 shows the distribution of electrolytes between the intermittent and 
persistent asthmatic groups. The distribution of hypernatremia, hypocalcaemia and 
hypophosphatemia between the intermittent and persistent group was found to be 
insignificant. The distribution of Hypokalemia and hypomagnesemia is found to 
be significant.  
 
 
 
 
 
Discussion: 
Bronchial asthma is one of the most common respiratory disorder that can 
start at any age and is seen to affect children as well as adults. It is a complex 
disorder that is characterized with episodes of breathlessness, wheeze and cough. 
The cough might be seen usually only at night or after an intensive exercise or 
exposure to an irritant. All the symptoms may be due to multiple factors producing 
responses differently in different individuals. The individual may have some 
respite from the symptoms in between episodes of bronchial attack. Although 
bronchial asthma is produced by multiple factors, they are all share one common 
thing- the ability to cause inflammation of the airways leading to airway 
obstruction further leading to difficulty to breathe normally.   
Remission is seen during the early childhood (puberty). Zein JG et al in their study 
reported that age is a risk factor for the severity of asthma between 18yrs to 45yrs. 
implying that the severity of asthma will be less during early childhood compared 
to those who become symptomatic during adulthood.90 
    The GINA classification serves as a basic guide line to treat asthma 
symptomatically rather than cure it completely. Treatment may include beta 
agonists, cortico steroids which may be inhaled or taken orally to relive the 
symptoms. Early detection and proper medication can help in decreasing the 
severity of the disease. This study was done to evaluate the electrolyte abnormality 
in asthmatic patients with a possibility of noting a difference in electrolyte levels 
among the persistent and intermittent asthmatic cases. 
The mean values of Serum sodium of intermittent and persistent asthmatic 
patients is 134.63± 0.9 mEq/L and 132.72 ± 1.93 mEq/L respectively. Both the 
mean values of serum Sodium are found to be lower than the control mean 136.54± 
2.56 mEq/L. The mean of serum Sodium in intermittent patients is closer to the 
control mean stating it is better than the persistent patient’s serum sodium. 
Statistically the difference in mean values were found to be significant, that is 
hyponatremia seen in intermittent and persistent groups with respect to the control 
group. The association between the two groups intermittent and persistent was 
found to be insignificant. The reference range being Na+: 136 – 145 mEq/L. The 
reason for hyponatremia could be the use of theophylline which can cause an 
elevated excretion of electrolytes and water suggested in the study done by Amin 
R.91  
The mean values of Serum potassium of intermittent and persistent 
asthmatic patients is 3.89 ± 0.89 mEq/L and 3.22 ± 0.19 mEq/L respectively. The 
mean value of serum potassium of the control patients is 4.37 ± 0.53 mEq/L which 
is more than that of intermittent asthmatic patients and persistent asthmatic 
patients. The reference range is 3.5 – 5.1 mEq/L. The mean of serum potassium 
levels of intermittent is found to be closer to the control groups mean serum 
potassium than the persistent groups mean of serum potassium hence better. The 
association between the two groups was found to be statistically significant. Whyte 
KF reported the presence of decreased serum potassium in asthmatic patients.10 
Whang et al. reported that when magnesium is depleted, side by side there 
is a corresponding decrease in serum potassium which is caused by the decreasing 
serum magnesium in impairing Na/K ATPase activity, along with increased efflux 
through K channels resulting in potassium loss through urine.92 The mean values 
of Serum Magnesium of intermittent and persistent asthmatic patients is 1.44 ± 
0.15 and 1.32 ± 0.62 mg/dl respectively. The mean value of serum magnesium for 
the control group is 1.96 ± 0.22 mg/dl. The normal reference range for serum 
Magnesium is 1.7-2.4 mg/dl. The mean serum magnesium of the intermittent 
group is found to be closer to the control group than the persistent group. This is 
statically significant also. All of the 44 asthmatic patients had hypomagnesaemia. 
Alamoudi OS reported that hypomagnesemia and hypophosphatemia are the two 
most common electrolyte disturbed in asthma.93  
The mean values of Serum Calcium among the intermittent and persistent 
asthmatic patients is 7.7 ± 0.67 mg/dl and 8.01 ± 0.74 mg/dl. Statistically there is 
significance when intermittent and persistent asthmatic group is compared with 
the control group individually. Although statistically insignificant, hypocalcaemia 
was seen in both the groups. The reference range being 8.6-10.3 mg/dl. Healthy 
subjects administered with IV β 2-agonists were reported with Hypocalcemia with 
an increase in the urinary excretion of calcium.94 
The mean values of Serum Phosphorus among the intermittent and 
persistent asthmatic patients is 2.29 ± 0.1 mg/dl and 2.29 ± 0.27 mg/dl 
respectively. The mean of the control group was 4.24 ± 0.57 mg/dl. The mean 
values of the control group has significance to the mean values of the persistent 
asthmatic patient group and intermittent patient groups individually. The 
asssociation was insignificant among the asthmatic groups. The reference range 
being 2.5-4.5 mg/dl. Alamoudi OS reported that hypomagnesemia and 
hypophosphatemia are the two most common electrolyte disturbed in asthma.93 
 A study in Emergency medical services of Denver General Hospital with 
23 patients with a history of asthma or chronic pulmonary disease showed that 
aggressive administration of nebulized Salbutamol during emergency treatment of 
acute bronchospasm was associated with significant decreases in serum 
Potassium, Magnesium and Phosphorus.95 
 Another study done at Calcutta National Medical College, Kolkata with 50 
asthmatic patients selected randomly who were attending the outpatients 
department of respiratory medicine showed 14 having hypomagnesaemia with 
tachypnoea who used long acting beta agonist, inhaled corticosteroids.96 
 A study done on 60 asthmatic patients in Adichunchanagiri Institute of 
Medical sciences and Hassan Government Medical college, Karnataka on their 
serum electrolytes levels during nebulised salbutamol therapy showed that serum 
electrolytes like magnesium, potassium and phosphorus decreased significantly in 
patients with acute severe asthma who were on treatment with nebulised 
salbutamol.97 
 
 
 
 
 
 
CONCLUSION: 
The study was done to evaluate the electrolytes in asthmatic patients who 
were attending SMIMS. The parameters that were taken into consideration were 
serum sodium, potassium, magnesium, phosphorus and calcium. As expected 
there was derangement of serum electrolytes in the asthmatic patient such as 
Hypokalemia, Hypomagnesaemia, Hyponatremia, and Hypophosphatemia. The 
asthmatic patients showed electrolyte abnormality in combinations. The study also 
showed the probable existence of hypocalcemia (below 8.5mg/dl) which was not 
statistically significant and probably warrants the need for a study involving a 
larger sample population to verify the significance if any.  A similar finding of 
insignificance is to be noted with respect to hypernatremia. The population of the 
study were people from in and around Kulasekharam a place known to have plenty 
of rubber trees and stone factories providing the aetiology for a probable dust 
induced or allergen induced bronchial asthma. 
  Various studies suggested the existence of serum electrolytes abnormality 
as a single entity or in combinations. This study was done to compare the 
electrolyte abnormality among the intermittent and persistent asthmatic cases with 
the hypothesis that as the intermittent patients required occasional medication their 
electrolytes would be better when compared with the persistent asthmatic group.  
The study showed that asthmatic patients presented with Hyponatremia, 
Hypokalemia, Hypomagnesaemia, Hypocalcemia or Hypophophatemia. The 
association of hypomagnesium and hypokalemia was seen strongly in asthmatic 
patients. Between the asthmatic groups serum potassium, serum sodium and serum 
magnesium of the intermittent asthmatic group is found to be better compared to 
the persistent group.  
 
Summary: 
Bronchial asthma is a common respiratory disease caused due to an airway 
inflammation following with difficulty in breathing normally.  It is caused by 
many factors. Treatment involves in alleviating the initial symptoms. Beta agonists 
is used as the first line of drug to treat asthma, which is known to cause 
abnormality in the serum electrolytes. 
The present case – control study involved 44 asthmatics as cases. Based on 
GINA classification for Asthma the asthmatic patients were grouped as 
Intermittent and persistent and compared with the control group’s serum 
electrolyte. The serum electrolyte which were considered for this study was 
sodium, potassium, magnesium, calcium and phosphorus. The cases were found 
to have various abnormalities such as Hypokalemia, Hypomagnesaemia, 
Hyponatremia, Hypophosphatemia and Hypocalcemia. The serum electrolyte in 
this study among the cases showed 3 electrolytes were better to persistent which 
could be statistically proved significant.  
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CONSENT FORM 
PART – II 
 The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not 
be directly beneficial to me but will help in the advancement of medical sciences. 
I confirm that I have understood the study and had the opportunity to ask questions. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that 
will normally be provided by the hospital being affected. I agree not to restrict the 
use of any data or results that arise from this study provided such a use is only for 
scientific purpose(s). I have been given an information sheet giving details of the 
study. I fully consent to participate in the study “A study of serum electrolytes 
abnormality in Asthmatics”. I give consent for withdrawing blood (5ml) from my 
body for your study. 
 
Serial no/Reference no: 
 
Name of the Participant:                     Address of the Participant. 
 
 
Contact number of the Participant: 
 
Signature/Thumb impression of the participant/Legal guardian 
Witness 
1. 
2. 
 
Date: 
Place: Kulasekharam 
CASE PROFORMA 
SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES 
KULASEKHARAM 
 
TITLE OF STUDY: “A study of serum electrolytes abnormality in Asthmatics”   
 
HOSPITAL NO       : 
SERIAL NO            : 
DATE                     : 
NAME                    : 
AGE                        : 
SEX                         : 
Occupation            : 
ADDRESS AND PHONE NO :  
 
BRIEF HISTORY   : 
  PRESENT C/O : 
  DURATION OF ASTHMA: 
  FREQUENCY OF ATTACKS: 
  LAST ATTACK : 
 
TREATMENT HISTORY  : 
  CURRENT MEDICATION: 
  DURATION OF USAGE: 
  ROUTE OF ADMINISTRATION: 
  FREQUENCY OF USE: 
  ANY OTHER MEDICINES FOR OTHER ILLNESS: 
 
 
GENERAL EXAMINATION: 
  PULSE:   BP:                   RESPIRATORY RATE: 
 
 
INVESTIGATION: Serum Potassium, Magnesium, Calcium, Phosphate and 
Sodium 
 
 
 
SIGNATURE OF INVESTIGATOR 
  
 
 
 
                                                                     MASTER CHART CONTROL 
    Name Age Sex Sodium Potassium Magnesium Calcium Phosphorus 
1 ALI FATHIMA 43 2. Female 135 3.7 2.5 8.6 4.5 
2 ANUSHA 25 2. Female 137 4.1 2 9 4.5 
3 SHOBA 41 2. Female 138 4.2 1.7 8.9 4.4 
4 JENNIFER 19 2.Female 136 3.8 2 8.9 4.3 
5 LATHIKA 31 2. Female 139 4.6 1.8 7.2 4.4 
6 SUBIN RAJ 32 1. Male 136 4.2 1.8 8.7 2.5 
7 SELVAN 34 1. Male 138 5.6 1.9 7.7 4.6 
8 JUSTIN 40 1. Male 143 4.6 2.1 8.5 4.5 
9 SASI KALA 58 2. Female 143 3.6 2 8.4 3 
10 BABU 50 1. Male 135 3.7 1.7 9 5.1 
11 PUORUSOTHAMAN 60 1. Male 132 4 2 9.2 4.4 
12 ACHUTHAN 54 1. Male 131 4.5 1.8 8.1 4.5 
13 MOHAN 54 1. Male 136 5.1 2.4 8.5 4.5 
14 DOMINIC XAVIER 55 1. Male 135 5 1.8 7.8 4.2 
15 ROSE MARY 56 2. Female 135 4.1 2.5 9.9 4.8 
16 SELBERI 33 1. Male 137 4.7 1.9 8.3 4.2 
17 SASI KUMAR 48 1. Male 138 5 2.4 9.4 4.6 
18 MANIKANDAN 25 1. Male 136 4.2 2 7.2 3.7 
19 SIVA KAMI 21 2. Female 137 4 2.3 9.9 4.4 
20 ANDREW JOBISH 41 1. Male 133 4.8 2.1 9.5 4.2 
21 MARY PUSHPABAI 52 2. Female 136 5.1 1.9 8.4 3.4 
22 VELAMMA 60 2. Female 141 3.5 2.1 9.1 4.8 
23 KRISHNAN 54 1. Male 135 4 1.8 7.9 3.6 
24 VIJAYA KUMAR 30 1. Male 140 5.1 1.9 8.4 4.8 
25 ALFRED 37 1. Male 134 5 2 8.2 3.8 
26 JEBA PRAKASH 48 1. Male 138 5.3 1.7 7.3 4 
27 SEKHAR 53 1. Male 136 4.9 1.8 8.6 4.1 
28 PICHANDIPILLAI 60 1. Male 136 4.7 1.8 7.9 3.9 
29 SOMY 32 2. Female 137 3.7 1.9 8.5 3.9 
30 CHINCHU 25 2. Female 139 4.2 1.7 9 5.1 
31 FLIPPO 34 1. Male 137 4.9 1.9 9.8 4.4 
32 THAPASIMUTHU 59 1. Male 137 4.6 1.6 9.1 5 
33 REMYA 23 2. Female 138 4.2 1.7 8.6 4 
34 SENTHIL 42 1. Male 137 4 1.8 9.2 4 
35 THANKA RAJ 43 1. Male 136 5.1 1.9 8 4.2 
36 SUBBURAM 54 1. Male 138 3.9 2.1 7.4 4.4 
37 AMARAVATHY 55 2. Female 137 3.9 1.7 7.4 4.4 
38 VILASINI 56 2. Female 135 3.9 1.9 8.1 4.4 
39 RAJAM 50 2. Female 137 4.3 1.8 8.5 3.5 
40 RAGAVAN NAIR 55 1. Male 134 3.9 2.1 8.6 4 
41 BENSAR 59 1. Male 130 3.9 2.2 8.7 2.9 
42 CHANDRASEKHARAN 48 1. Male 138 4.1 2.1 8.8 5 
43 RAMAR 54 1. Male 135 5 2.2 8.9 5 
44 DAISY 58 2. Female 137 4 2.1 9.1 4.7 
 
MASTER CHART CASES 
Date Name Age Sex Sodium Potassium Magnesium Calcium Phosphorus 
Intermittent / 
persistent 
<1symptom 
per week 
<2 nocturnal 
symptoms 
1 KUMAR 48 1.Male 136 4.6 1.5 7.7 2.2 i 1.Yes 1.Yes 
2 MANIKANDAN 19 1. Male 134 6.3 1.5 7.6 2.4 i 1. Yes 1. Yes 
3 SURENDRAN 60 1. Male 134 3.1 4 6.6 2.3            p 2. No 2. No 
4 ASIA 20 2. Female 135 3.5 1.3 7.6 2.3 i 1. Yes 1. Yes 
5 VIDHYA 32 2. Female 135 4.3 1 7.2 2.4 i 1. Yes 1. Yes 
6 ESSAKI RAJ 26 1. Male 135 4.9 1.5 8.4 2.1 i 1. Yes 1. Yes 
7 SULAIKA BEEVI 56 2. Female 133 4.6 1.4 8.4 2.4 i 1. Yes 1. Yes 
8 JOHNSON 60 1. Male 134 5 1.3 7.6 2.3 i 1. Yes 1. Yes 
9 NASZEERA 46 2. Female 130 3.7 1.1 7.9 3.4 p 2. No 2. No 
10 ALEX 18 1. Male 134 5.1 1.5 8.2 2.2 i 1. Yes 1. Yes 
11 SHINY 34 2.Female 134 3.1 1.5 8.3 2.3 p 2.No 2.No 
12 THANKAMMAL 58 2. Female 133 4.8 1.6 8.1 2.3 i 1. Yes 1. Yes 
13 KUMARI JEYA 52 2. Female 134 3.1 1.5 6.7 2.3 i 1. Yes 1. Yes 
14 THANKAMMA 53 2. Female 135 3.1 1.2 6.8 2.4 i 1. Yes 1. Yes 
15 MINI THANKAM 45 2. Female 135 3.2 1.4 8.3 2.2 i 1. Yes 1. Yes 
16 KRISHNAN 54 1. Male 131 2.7 1.2 5.8 2.1 p 2. No 2. No 
17 KANNAN 54 1. Male 130 3.1 1.2 6.6 2.4 p 2. No 2. No 
18 POOMANI 42 2. Female 134 3.4 1.4 7.6 2.3 i 1. Yes 1. Yes 
19 SAMUVEL 47 1. Male 134 3.3 1.3 8.1 2.4 i 1. Yes 1. Yes 
20 RADHA NAIR 54 2. Female 135 3.1 1.6 6 2.4 i 1. Yes 1. Yes 
21 NESAYYAN 60 1. Male 135 3.4 1.5 8.4 2.2 i 1. Yes 1. Yes 
22 ESWARAPRASAD 57 1. Male 136 3.4 1.5 7.3 2.1 i 1. Yes 1. Yes 
23 MERLIN 26 2. Female 134 3.3 1.6 6.8 2.1 i 1. Yes 1. Yes 
24 GANAPATHY 58 1. Male 135 3.2 1.4 8.3 2.3 i 1. Yes 1. Yes 
25 JOHN PAUL 30 1. Male 136 3.3 1.6 7.6 2.3 i 1. Yes 1. Yes 
26 THANKA RAJ 50 1. Male 134 3.4 1.5 8.4 2.4 i 1. Yes 1. Yes 
27 ELIZABETH 48 2. Female 136 3.4 1.6 8.3 2.4 i 1. Yes 1. Yes 
28 SUBRAMANIAN 48 1. Male 132 3.1 1.2 8.5 2.1 p 2.No 2.No 
29 GOBINATH 45 1. Male 132 3.3 1.3 8 2.4 p 2.No 2.No 
30 GOMATHY 53 2. Female 134 3.3 1.4 8.1 2.3 p 2.No 2.No 
31 ABDUL WAHAB 55 1. Male 134 3.4 1.4 8.4 2.2 p 2.No 2.No 
32 GEETHA 18 2. Female 131 3.2 1 8.5 2.1 p 2.No 2.No 
33 PAPPA 45 2. Female 134 3.2 0.8 8.3 2.4 p 2.No 2.No 
34 SOUNDARA BAI 56 2. Female 134 3.3 0.9 8.2 2.3 p 2.No 2.No 
35 FELSITAL MARY 48 2. Female 133 3.2 1.3 8.1 2.2 p 2.No 2.No 
36 SUSHMITHA 21 2. Female 128 3.1 1.4 8.5 2.1 p 2.No 2.No 
37 RENY JOY 29 2. Female 132 3.2 1.2 8.6 2.1 p 2.No 2.No 
38 KARTHIKA 23 2. Female 134 3.1 1.1 8.3 2.4 p 2.No 2.No 
39 RENJITH 32 1. Male 133 3.4 1.3 8.8 2.3 p 2.No 2.No 
40 SHYMA 37 2. Female 135 3.4 1.1 8.2 2.2 p 2.No 2.No 
41 RAVI CHANDRAN 41 1. Male 135 3.4 1.1 8.5 2.1 p 2.No 2.No 
42 CHELLATHAI 60 2. Female 136 3.3 1.3 7.5 2.3 p 2.No 2.No 
43 RAJENDRAN 41 1. Male 132 3.2 1.3 8.3 2.2 p 2.No 2.No 
44 LOBISAL 59 2. Female 132 3.1 1 8.3 2.2 p 2.No 2.No 
